This week Moderna, Inc. announced that the UK regulator, the MHRA, had begun a rolling review of its COVID-19 vaccine candidate, mRNA-1273. The company is also planning to file the product with the European Medicines Agency, and has begun a rolling submission to Health Canada.
The announcement of the UK review follows the publication of positive results of a preclinical viral challenge of mRNA-1273 and...








